As an increasing number of immunotherapy treatments find their way into the front-line treatment of solid tumors, including lung cancer, clinicians are often faced with a lack of options when choosing systemic therapies after chemoimmunotherapy.  During the Education Session, “Choosing Systemic Therapies After Chemoimmunotherapy in NSCLC” three speakers provided updates on the current second-line options…